Aimmune Therapeutics

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Aimmune Therapeutics sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 8 completed later-stage tilt top decile by trial count

Aimmune Therapeutics: 10 sponsored US clinical trials, 1 recruiting.

Aimmune Therapeutics sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 8 completed. 6 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peanut Allergy, with 5 trials.

Top-decile sponsor footprint

Aimmune Therapeutics ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING NA

Aimmune Longitudinal Collaboration Study

NCT07218640
TERMINATED Phase 2

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

NCT04056299
COMPLETED Phase 3

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

NCT03736447
COMPLETED Phase 3

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

NCT03292484
COMPLETED Phase 3

AR101 Real-World Open-Label Extension Study

NCT03337542
COMPLETED Phase 3

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)

NCT03126227
COMPLETED Phase 3

PALISADE Follow-on Study (ARC004)

NCT02993107
COMPLETED Phase 3

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

NCT02635776
COMPLETED Phase 2

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

NCT02198664
COMPLETED Phase 2

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

NCT01987817

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 3 6

Therapeutic Areas

Peanut Allergy 5
Dietary Fiber 1
Microbiome Composition 1
Stool Spore Colony Forming Units 1
Stress 1

Where Aimmune Therapeutics enrollment is open (later-stage tilt)

1 recruiting of 10 indexed (10% open); 8 completed (80%).

Phase mix: 6 late (III/IV) vs 3 early (I/II) (later-stage heavy).

Top condition: Peanut Allergy (5 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Aimmune Therapeutics: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Aimmune Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Aimmune TherapeuticsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)Ascension Health
Aimmune Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aimmune Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aimmune Therapeutics page

10 registered trials is a research-attention snapshot, not an endorsement of Aimmune Therapeutics or any single study.

  • 1 of Aimmune Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Peanut Allergy is the condition Aimmune Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peanut Allergy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Aimmune Therapeutics pipeline card: 10 registered trials from official public datasets.Report a data error.